Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed as antihyperglycemic agents, have demonstrated significant cardiovascular and renal benefits that extend beyond glucose lowering [4]. Empagliflozin has emerged as a leading agent within this class as a leading therapeutic agent, with pivotal trials demonstrating its potential to modify the clinical trajectory of cardiovascular disease [5]. Empagliflozin is an SGLT2 inhibitor initially approved for glycemic control in patients with type 2 diabetes [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.